Insider Buying: 4basebio (LON:4BB) Insider Purchases 2,650 Shares of Stock February 17, 2026 by InsiderTrades.com Share Key Points Insider purchase: Amy Walker bought 2,650 shares on Feb 13 at an average of GBX 586 per share, a transaction totalling about £15,529. Stock and valuation snapshot: Shares opened at GBX 569.20 with a 52‑week range of GBX 520–1,220, 50/200‑day moving averages of GBX 597.71/727.91, a market cap of £88.14m, a negative P/E (‑5.75) and a high debt‑to‑equity ratio (201.47). Company focus: 4basebio supplies GMP‑grade synthetic DNA and develops non‑viral nanoparticles for gene therapies and gene‑based vaccines, targeting clinical development and commercialization. 4basebio PLC (LON:4BB - Get Free Report) insider Amy Walker purchased 2,650 shares of the business's stock in a transaction that occurred on Friday, February 13th. The shares were purchased at an average cost of GBX 586 per share, with a total value of £15,529. 4basebio Price PerformanceShares of LON:4BB opened at GBX 569.20 on Tuesday. 4basebio PLC has a 52 week low of GBX 520 and a 52 week high of GBX 1,220. The company has a 50-day moving average price of GBX 597.71 and a 200 day moving average price of GBX 727.91. The company has a market cap of £88.14 million, a P/E ratio of -5.75 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. 4basebio Company Profile (Get Free Report)4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.Recommended StoriesFive stocks we like better than 4basebioYour Bank Account Is No Longer SafeNvidia CEO Issues Bold Tesla CallBuy this Gold Stock Before May 2026What a Former CIA Agent Knows About the Coming CollapseThis $15 Stock Could Go Down as the #1 Stock of 2026This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected]. Insider Buying or Selling at 4basebio? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for 4basebio and related companies. From Our PartnersThis makes me furiousI Called Black Monday. Now I'm Calling March 26! I predicted the 1987 crash six weeks early. I called the f...The Oxford Club | SponsoredElon Musk: This Could Turn $100 into $100,000CNBC: "This Is the Big Market Event of 2026." The New York Times predicted this new Elon Musk opportunity "...Brownstone Research | SponsoredSilver paying 20% dividend. Plus 68% share gainsSilver Is Now a Growth AND Income Play For decades, silver paid nothing. That just changed. One tiny ETF is...Investors Alley | SponsoredWhat Expenses Can Be Deducted From Capital Gains Tax This Year?If you've built substantial wealth, capital gains taxes may quietly erode far more of your investment returns ...SmartAsset | SponsoredVWAV: Riding the Defense SurgeAs U.S. and global defense budgets accelerate into a new era, the nature of warfare is shifting rapidly toward...Equiscreen | SponsoredAmerica’s 1776 happening againHe’s one of the most successful investment analysts in America over the past 30 years… and he’s just gone publ...Porter & Company | SponsoredSilver $500? The "Deficit Math" says it's possible.Gold just broke past $5,000 an ounce, and Advantage Gold is hosting a live 2026 Gold & Silver Summit on March ...Advantage Gold | SponsoredGilder: Don’t Buy AI Stocks, Do This InsteadTrump’s $200 Billion Revolution Changes Everything AI With 100X faster processing power... and 90% less ene...Eagle Publishing | Sponsored Free Insider Buying and Selling Newsletter Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report. From Our PartnersThis makes me furiousI Called Black Monday. Now I'm Calling March 26! I predicted the 1987 crash six weeks early. I called the f...The Oxford Club | SponsoredElon Musk: This Could Turn $100 into $100,000CNBC: "This Is the Big Market Event of 2026." The New York Times predicted this new Elon Musk opportunity "...Brownstone Research | SponsoredSilver paying 20% dividend. Plus 68% share gainsSilver Is Now a Growth AND Income Play For decades, silver paid nothing. That just changed. One tiny ETF is...Investors Alley | SponsoredWhat Expenses Can Be Deducted From Capital Gains Tax This Year?If you've built substantial wealth, capital gains taxes may quietly erode far more of your investment returns ...SmartAsset | SponsoredVWAV: Riding the Defense SurgeAs U.S. and global defense budgets accelerate into a new era, the nature of warfare is shifting rapidly toward...Equiscreen | Sponsored Most Read This MonthWhy Amprius Insiders Are Selling—and Why Bulls Aren’t PanickingInsiders Rang in the New Year Selling These Stocks, Buyers BewareMarriott Vacations Worldwide: Insider Buying and Capital ReturnInsiders Piled Into These 3 Stocks in Q4—One Stands OutInsider Buying: CRISPR Therapeutics (NASDAQ:CRSP) Insider Buys $49,703.68 in StockInsider Selling: Credo Technology Group (NASDAQ:CRDO) Director Sells 1,875 Shares of StockInsider Selling: Post (NYSE:POST) Director Sells 6,983 Shares of StockInsider Selling: Northrop Grumman (NYSE:NOC) CEO Sells 20,000 Shares of StockRecent ArticlesBrixton Metals (CVE:BBB) Director Luogang Chen Buys 10,000 SharesJason Arbuckle Sells 190 Shares of Zions Bancorporation, N.A. (NASDAQ:ZION) StockInsider Selling: Ardelyx (NASDAQ:ARDX) CFO Sells 2,033 Shares of StockInsider Buying: Avita Medical (NASDAQ:RCEL) CFO Acquires 3,000 Shares of StockAmeresco (NYSE:AMRC) Director Nickolas Stavropoulos Sells 400 Shares of StockDouglas Strange Sells 205 Shares of Ameris Bancorp (NASDAQ:ABCB) StockBiodesix (NASDAQ:BDSX) CEO Scott Hutton Sells 1,490 SharesPromis Neurosciences (NASDAQ:PMN) Insider Buys $25,005.15 in Stock
